AAD
  • Meeting Program
  • Registration
  • Daily Coverage
  • Photo Gallery
  • Samples & Solutions
Topics
  • Daily Coverage
  • Photo Gallery
  • Samples & Solutions
Resources
  • Meeting Program
  • Registration
Facebook iconInstagram iconTwitter X icon
Aug 04, 2021

Oncodermatology pearls to provide relief for cancer patients

With today’s growing list of oncologic therapies, adverse effects have expanded to include a wider array beyond hair loss.


Azael Freites-Martinez, MD, IFAAD
Azael Freites-Martinez, MD, IFAAD

Hair loss has long been the most recognizable adverse effect of cancer treatment. Yet, with today’s growing list of oncologic therapies, adverse effects have expanded to include a wider array of conditions that include the hair as well as the skin and nails.

Arming dermatologists with the best level of evidence and therapeutic pearls to manage common outpatient conditions associated with cancer treatment will be the focus of Friday’s session, “The Skin of Cancer Patients: MASCC Supportive Oncodermatology Pearls for General Dermatologist (U007)." Speakers will spotlight real cases and outcomes, according to session director Azael Freites-Martinez, MD, IFAAD. Dr. Freites-Martinez is co-chair of the EADV Taskforce of Oncology for Cancer Patients, Dermatologists with a fellowship in oncodermatology at Memorial Sloan Kettering Cancer Center in New York, and is an associate professor at the Universidad Europea in Madrid.

“The most relevant adverse events in breast cancer patients, which is the leading cancer in the world among women, involve those attributed to cytotoxic chemotherapies usually given in breast cancer, stages II to IV,” Dr. Freites-Martinez said. “This includes nail onycholysis, hand and foot syndrome, chemotherapy-induced alopecia, persistent alopecia after chemotherapy, and radiation-induced dermatitis.”

Friday’s session will separate the conditions by cancer type, examining those related to breast, lung, and colon cancer as well as melanoma. In colon and lung cancer, for example, adverse effects go beyond those associated with cytotoxic chemotherapies. They include acneiform rash, due to targeted therapy and novel immunotherapies (also given in melanoma), such as immune checkpoint inhibitors, and include maculopapular rash, itch, and other inflammatory skin reactions.

“For patients with lung cancer and melanoma, immunotherapy is often employed; therefore, pruritus and other dermatitides are quite frequent,” said session co-director Emily Smith, MD, FAAD, assistant professor of dermatology and dermatopathology and program leader of the multi-disciplinary cutaneous oncology and oncodermatology program at the University of Missouri. “Patients with colon cancer and lung cancer treated with targeted therapies are more likely to develop papulopustular eruptions and complications of xerosis.”

According to Dr. Smith, it’s important that all patients undergoing systemic treatment for cancer ascribe to a good, consistent skin care routine. This includes sensitive skin care techniques, such as frequent emollient use. Photoprotection also is important, she said. In general, the eruptions that develop secondary to systemic cancer treatments are treated like their non-cancer treatment-related counterparts. Aggressive management is key to keeping toxicities at bay, improving the patient’s quality of life and ensuring that treatment may proceed without interruption, she said.

Dr. Freites-Martinez said Friday’s roster of session speakers will offer pearls that have been effective for their patients, including the use of lotions and creams with 10-15% lactate in melanoma patients receiving immunotherapies to prevent and treat skin dryness and itch, soaking nails in diluted white vinegar (rice vinegar) to treat and prevent common nail adverse events in breast cancer patients receiving cytotoxic chemotherapies, and the use of 5% topical minoxidil for persistent chemotherapy-induced alopecia and the one observed in breast cancer patients treated with endocrine therapies.

“Treat what you see,” Dr. Smith said. “Patients with papulopustular eruptions often respond well to topical, oral antibiotic, and corticosteroid therapy. If they do not, always consider the possibility of a secondary infection.”

Dr. Smith also recommended topical timolol gel-forming solution for relief of fissuring in patients with hand-foot-skin reaction secondary to targeted therapies, scalp and hand/foot cooling during infusions of cytotoxic chemotherapy to relieve the severity of anagen effluvium, palmoplantar dysesthesia, and nail changes associated with these therapies, and Aprepitant for immunotherapy-induced pruritus. 


Interesting Stories
DermWorld November | Scent-itive skin
Presented by AAD
DermWorld November | Scent-itive skin
DermWorld March | Publishing profiteers
Presented by AAD
DermWorld March | Publishing profiteers
DermWorld April | Shedding light on treatments for female pattern hair loss
Presented by AAD
DermWorld April | Shedding light on treatments for female pattern hair loss
DermWorld February | Glow Up
Presented by AAD
DermWorld February | Glow Up
DermWorld December | Disease reporting
Presented by AAD
DermWorld December | Disease reporting
DermWorld  January | Scar solutions
Presented by AAD
DermWorld January | Scar solutions
More in Summer Meeting 2021
Peter Lio, MD, FAAD
Summer Meeting 2021
The secrets of minimizing pain
Aug 11, 2021
Lawrence S. Chan, MD, FAAD
Summer Meeting 2021
Biomedical advancements impact dermatologic diagnosis and treatment
Aug 11, 2021
Todd Schlesinger, MD, FAAD
Summer Meeting 2021
Update on managing advanced skin cancer
Aug 11, 2021
Hensin Tsao, MD, PhD, FAAD
Summer Meeting 2021
HPV vax, psoriasis biologics, and caregiver quality of life highlight FiRST session
Aug 11, 2021
07e
Summer Meeting 2021
Summer Meeting packed a welcome punch
Aug 11, 2021
Mario E. Lacouture, MD, FAAD
Summer Meeting 2021
Oncodermatology takes the stage at Fox Lectureship
Aug 06, 2021
Julie Gerberding, MD, MPH
Summer Meeting 2021
COVID-19: A “predictable surprise”
Aug 06, 2021
Aimee Payne, MD, PhD, FAAD
Summer Meeting 2021
Frost Lectureship traces mPV treatment’s path from lab to clinical trial
Aug 06, 2021
2020 Gold Medal Presentation | Professor R. Rox Anderson, MD (left), Lancer Endowed Chair in Dermatology, Harvard Medical School and Director, Wellman Center for Photomedicine at Mass. General Hospital. 2021 Gold Medal Presentation | Dirk Michael Elston, MD, FAAD (right), Medical University of South Carolina.
Summer Meeting 2021
Two physicians honored with AAD Gold Medal awards
Aug 05, 2021
Alina G. Bridges, DO, FAAD
Summer Meeting 2021
New science, technology, and dedication improve dermatopathology
Aug 05, 2021
Sm21 F008 1526e
Summer Meeting 2021
How to have mindful, effective conversations with patients
Aug 05, 2021
Sergey Rekhtman, MD, FAAD, PharmD, MPH, and Sheila Shaigany, MD, FAAD
Summer Meeting 2021
Lessons from COVID-19’s cutaneous manifestations
Aug 05, 2021
AAD
Facebook iconInstagram iconTwitter X icon
© Ascend Media All rights reserved. DermWorld Meeting News Central is a publication of the American Academy of Dermatology.